Stem cell technology has unlocked a world of potential treatments for almost every kind of disease. International Stem Cell offers an especially valuable foundation for such treatments through its development of parthenogenetic stem cells (hpSC), non-embryonic histocompatible human stem cells. Parthenogenesis promises to significantly advance the field of regenerative medicine by addressing the problem of immune-rejection. This is because parthenogenesis utilizes unfertilized human eggs to create stem cells that can be immune-matched to millions of people, meaning that a relatively small number of hpSC lines could provide sufficient immune-matched cells to cover a large percentage of the world's population.
ISCO scientists are now performing research to verify that such parthenogenetic stem cell lines can be successfully used to treat a variety of diseases, including chronic liver disease. Chronic liver disease (including hepatitis C) is the third most common cause of death due to chronic diseases in persons 35 to 64 years old. Roughly 3 million Americans are chronically infected with the hepatitis C virus, and approximately 12,000 Americans die annually from the disease. Cirrhosis and hepatitis taken together claim over 30,000 lives annually in the U.S. alone, and health care costs for chronic and acute liver disease in the U.S. are estimated to range from $60 billion to over $100 billion.
The company's scientific team is developing better methods to create pure populations of hepatocyte, the cells that make up most liver tissue, for use in transplantation, using HLA homozygous parthenogenetic stem cell lines to avoid the cells being immune rejected. UniStemCell bank, established by ISCO, is the life science industry's first collection of non-embryonic histocompatible human stem cells available for research and commercial use.
For additional information, visit www.InternationalStemCell.com
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net